InsiderSignal.AI

InsiderSignal.ai

IDYA - Ideaya Biosciences, Inc.

Insider Purchase by Stein Jeffrey (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Stein Jeffrey, serving as Dir at Ideaya Biosciences, Inc. (IDYA), purchased 50,000 shares at $32.96 per share, for a total transaction value of $1,647,890.00. Following this transaction, Stein Jeffrey now holds 61,007 shares of IDYA.

This purchase represents a 454.00% increase in Stein Jeffrey's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 2, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 2, 2026, meaning the disclosure happened on the same day as the trade.

Ideaya Biosciences, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Stein Jeffrey

Dir

Jeffrey Stein, Ph.D., age 70, is the President, Chief Executive Officer, and Director of Cidara Therapeutics, Inc. (CDTX), a role he has held since January 2014.[[1]](https://fintool.com/app/research/companies/CDTX/people/jeffrey-stein)[[2]](https://www.kauffmanfellows.org/fellows/jeffrey-stein)[[3]](https://www.terrapinn.com/conference/world-antiviral-congress/speaker-jeff-STEIN.stm) Under his leadership, Cidara focuses on developing novel anti-infective therapies, particularly in the antifungal space to address high unmet needs in invasive fungal infections.[[5]](https://www.youtube.com/watch?v=5-XS4COr5hs)[[7]](https://www.cidara.com/about/) Stein brings extensive experience in biotechnology and anti-infectives, having previously served as CEO of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in 2013, where he advanced the antibacterial drug tedizolid to FDA approval.[[1]](https://fintool.com/app/research/companies/CDTX/people/jeffrey-stein)[[2]](https://www.kauffmanfellows.org/fellows/jeffrey-stein)[[3]](https://www.terrapinn.com/conference/world-antiviral-congress/speaker-jeff-STEIN.stm) Earlier, he was a Venture Partner and Kauffman Fellow at Sofinnova Ventures, opening their San Diego office; co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, acquired by Pfizer in 2005; and Principal Scientist at Diversa Corporation and Agouron Institute.[[1]](https://fintool.com/app/research/companies/CDTX/people/jeffrey-stein)[[2]](https://www.kauffmanfellows.org/fellows/jeffrey-stein) He earned his Ph.D. with graduate work as a NASA Graduate Student Researcher Fellow at UCSD and conducted postdoctoral research as an Alexander Hollaender Distinguished Fellow at Caltech.[[1]](https://fintool.com/app/research/companies/CDTX/people/jeffrey-stein)[[2]](https://www.kauffmanfellows.org/fellows/jeffrey-stein) Stein also serves on the board of IDEAYA Biosciences and previously Paratek Pharmaceuticals, and is founding Chairman and President of the Antibiotics Working Group.[[1]](https://fintool.com/app/research/companies/CDTX/people/jeffrey-stein)[[2]](https://www.kauffmanfellows.org/fellows/jeffrey-stein)

View full insider profile →

Trade Price

$32.96

Quantity

50,000

Total Value

$1,647,890.00

Shares Owned

61,007

Trade Date

Monday, March 2, 2026

3 days ago

SEC Filing Date

Monday, March 2, 2026

HEALTHCAREBIOTECHNOLOGY

About Ideaya Biosciences, Inc.

Company Overview

No company information available
View news mentioning IDYA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4442851

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime